Kathrine Meyers1, Sarit A Golub. 1. aAaron Diamond AIDS Research Center, New York, New York, USA bHunter College of the City University of New York.
Abstract
PURPOSE OF REVIEW: Broad-based access, uptake, and dissemination of daily oral HIV preexposure prophylaxis (PrEP) have been slow, despite strong evidence for efficacy. Effective and efficient implementation of long-acting HIV prevention products will require both analysis of the dynamics and determinants of daily oral PrEP implementation and identification of the distinct challenges and opportunities inherent in emerging technologies. RECENT FINDINGS: Evidence suggests the importance of addressing implementation issues at three levels: patient, provider, and system. Patient-level factors include targeted education and messaging, tailored supports to enhance acceptability and uptake, and effective strategies for promoting adherence/persistence and retention in care. Provider-level factors include engaging a broad mix of providers, while ensuring adequate training and support for patient assessment, counseling, and follow-up. Systems-level factors include optimal delivery modalities, resource allocation, and ensuring access to populations most in need of new prevention options. SUMMARY: Formative social/behavioral research must be undertaken proactively to prepare for and address future implementation challenges and reduce the gap between proving efficacy in clinical trials and assuring real-world effectiveness. Conceptualizing new HIV prevention technologies as behavioral interventions at the level of the patient, provider, and system will be paramount to effective and efficient implementation.
PURPOSE OF REVIEW: Broad-based access, uptake, and dissemination of daily oral HIV preexposure prophylaxis (PrEP) have been slow, despite strong evidence for efficacy. Effective and efficient implementation of long-acting HIV prevention products will require both analysis of the dynamics and determinants of daily oral PrEP implementation and identification of the distinct challenges and opportunities inherent in emerging technologies. RECENT FINDINGS: Evidence suggests the importance of addressing implementation issues at three levels: patient, provider, and system. Patient-level factors include targeted education and messaging, tailored supports to enhance acceptability and uptake, and effective strategies for promoting adherence/persistence and retention in care. Provider-level factors include engaging a broad mix of providers, while ensuring adequate training and support for patient assessment, counseling, and follow-up. Systems-level factors include optimal delivery modalities, resource allocation, and ensuring access to populations most in need of new prevention options. SUMMARY: Formative social/behavioral research must be undertaken proactively to prepare for and address future implementation challenges and reduce the gap between proving efficacy in clinical trials and assuring real-world effectiveness. Conceptualizing new HIV prevention technologies as behavioral interventions at the level of the patient, provider, and system will be paramount to effective and efficient implementation.
Authors: Rob Horne; Kate Faasse; Vanessa Cooper; Michael A Diefenbach; Howard Leventhal; Elaine Leventhal; Keith J Petrie Journal: Br J Health Psychol Date: 2012-04-23
Authors: Susan G Sherman; Kristin E Schneider; Ju Nyeong Park; Sean T Allen; Derrick Hunt; C Patrick Chaulk; Brian W Weir Journal: Drug Alcohol Depend Date: 2018-10-22 Impact factor: 4.492
Authors: Christine Tagliaferri Rael; Michelle Martinez; Rebecca Giguere; Walter Bockting; Caitlin MacCrate; Will Mellman; Pablo Valente; George J Greene; Susan Sherman; Katherine H A Footer; Richard T D'Aquila; Alex Carballo-Diéguez Journal: AIDS Behav Date: 2018-11
Authors: Bhavesh D Kevadiya; Brendan Ottemann; Insiya Z Mukadam; Laura Castellanos; Kristen Sikora; James R Hilaire; Jatin Machhi; Jonathan Herskovitz; Dhruvkumar Soni; Mahmudul Hasan; Wenting Zhang; Sarella Anandakumar; Jered Garrison; JoEllyn McMillan; Benson Edagwa; R Lee Mosley; Richard W Vachet; Howard E Gendelman Journal: Theranostics Date: 2020-01-01 Impact factor: 11.556